| Overview |
| bs-9736R |
| D53 Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TPD52L1/D53 |
| 101-200/204 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 7164 |
| D53; D54; hD53; hD54; Tpd52l1; TPD52L2 TPD53_HUMAN; Tumor protein D52 like 1; Tumor protein D52 like 2; Tumor protein D52-like 1; Tumor protein D53; Tumor protein D54. |
| The cell commits to dividing during the G2/M phase transition, and the timing of mitotic entry is tightly regulated to guarantee correct chromosome segregation. D53, also referred to as tumor protein D52-like 1 (TPD52L1), is a coiled-coil motif-bearing member of the D52 tumor protein family. D53 intereacts with 14-3-3, a negative regulator of the G2/M transition, in breast cancer cells. Expression of D53 is highly upregulated at the G2/M phase transition in breast cancer cell lines, and deregulated expression of this protein can adversely affect the completion of mitosis. D53 may function as a signaling intermediate and/or regulator of vesicle trafficking and cell proliferation. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz